Life Science Investing Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
Life Science Investing Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
Life Science Investing Exelixis to Webcast Virtual 2025 Research & Development Day on Wednesday, December 10, 2025
Life Science Investing Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Life Science Investing Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Life Science Investing SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
Life Science Investing Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
Life Science Investing Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
Life Science Investing Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
Life Science Investing Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
LAURION Intersects High-Grade Gold, Silver and Zinc at Ishkoday A-Zone/McLeod/CRK Zone, Confirming Structural Continuity Along Mineralized Corridor
